FDA Rejects Over 889,000 Tobacco Applications for Noncompliance

Oct.17.2022
FDA Rejects Over 889,000 Tobacco Applications for Noncompliance
FDA rejects 889,000 tobacco product applications while accepting over 1,600, mostly for e-cigarettes and e-liquids. Warning letters sent to manufacturers and retailers.

The US Food and Drug Administration (FDA) has announced that it has issued more than 889,000 Refuse to Accept (RTA) letters as of October 7, to pre-market tobacco product applications (PMTAs) that do not meet acceptance criteria.


The organization also announced that the FDA has received over 1,600 applications, the majority of which are for electronic cigarettes or e-liquid products.


Although the review process is ongoing, the FDA remains vigilant in regulating the market and will continue to use our compliance and enforcement resources to curb the illegal marketing of non-tobacco nicotine products. To date, the FDA has issued more than 60 warning letters to manufacturers, including popular brands among young people such as Puff Bar," stated the FDA in a press release. "The warning letters include products that have submitted applications but have received negative actions from the agency.


The FDA has sent over 300 warning letters to retailers demanding that they cease selling synthetic nicotine e-cigarette products to minors, and has imposed civil fines on two retailers for selling e-cigarette products to minors.


So far, the FDA has not authorized any synthetic nicotine e-cigarette products. Therefore, all synthetic nicotine e-cigarette products on the market are being sold illegally and are at risk of FDA enforcement action," said the FDA. "Retailers or distributors selling or distributing unauthorized e-cigarettes are breaking the law and those engaging in such behavior will face FDA enforcement risks, such as seizures, injunctions, or civil fines.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness and accuracy of the content. The translation of this article is solely for industry exchange and research purposes.


Due to limitations in our translation abilities, the translated article may not fully represent the original text. Therefore, please refer to the original text for accurate information.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.


The ownership of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
Indonesia to Step Up Vape Surveillance as Concerns Rise Over Drug-Laced E-Cigarettes
Indonesia to Step Up Vape Surveillance as Concerns Rise Over Drug-Laced E-Cigarettes
Indonesia will strengthen surveillance of vapes amid growing concerns over drug-laced e-cigarettes. The National Food and Drug Monitoring Agency, or BPOM, will soon take charge of monitoring nationwide vape distribution and said it will work with the National Narcotics Agency, or BNN. BNN recently floated a plan to completely ban e-cigarettes, saying a total ban was the only way to prevent liquid narcotics.
May.11 by 2FIRSTS.ai
 Bangladesh Approves Amended Tobacco Control Law Expanding Ad Bans and Smoke-Free Areas
Bangladesh Approves Amended Tobacco Control Law Expanding Ad Bans and Smoke-Free Areas
Bangladesh’s new government has approved a broad tobacco control amendment that bans tobacco advertising, promotion and display across print, electronic, digital and social media, entertainment platforms and points of sale. The law does not cover newer products such as vapes, heated tobacco products, electronic nicotine delivery systems or nicotine pouches.
Apr.22 by 2FIRSTS.ai
Ukrainian Prosecutors and Economic Security Bureau Dismantle Illegal Vape Liquid Network Worth About UAH 30 Million
Ukrainian Prosecutors and Economic Security Bureau Dismantle Illegal Vape Liquid Network Worth About UAH 30 Million
Ukraine’s Office of the Prosecutor General and the Bureau of Economic Security said they uncovered an illegal production and sales scheme for e-cigarette liquids that had been operating in Ukraine since 2023.
Apr.14 by 2FIRSTS.ai
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12
Imperial Brands Expects Low-Single-Digit Tobacco and NGP Net Revenue Growth in H1
Imperial Brands Expects Low-Single-Digit Tobacco and NGP Net Revenue Growth in H1
Imperial Brands released a trading update on April 14, reiterating its FY26 guidance and saying its 2030 transformation has started positively. The company said it still expects low-single-digit tobacco net revenue growth, double-digit NGP net revenue growth, 3.00% to 5.00% growth in Group adjusted operating profit, at least high-single-digit earnings per share growth, and at least GBP 2.2 billion in free cash flow for the full year.
Apr.14 by 2FIRSTS.ai